At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older, male or female
- ✓History of total or near total thyroidectomy OR hypothyroidism on replacement therapy
- ✓For non-thyroidectomized patients: at least 3 years of replacement therapy (≥1.2 mcg/kg LT4) with <5% thyroid uptake on 24-hour I-123 scan
- ✕BMI ≤20 or ≥30 kg/m²
- ✕Metastatic thyroid cancer or thyroid cancer history with high recurrence risk requiring suppressive therapy
- ✕Significant thyroid residual (>1 mL by ultrasound in thyroidectomized patients; >5% uptake on I-123 scan in non-thyroidectomized patients)
- ✕History or symptoms of cardiovascular disease including paroxysmal supraventricular tachycardia, atrial fibrillation, syncope, or use of antihypertensive/cardiac medications
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Peripheral Thyroid Hormone Conversion and Glucose and Energy Metabolism
In Brief
A Phase 2 clinical trial evaluating Liothyronine and Levothyroxine for Thyroid Diseases. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This study will examine how two thyroid preparations-levothyroxine (T4) and liothyronine (T3)-affect fat and cholesterol metabolism, blood sugar regulation, and thyrotropin secretion in patients who have had their thyroid gland removed. Results of the study may help in the development of better therapies to optimize blood sugar and cholesterol levels in some patients. Patients 18 years of age or older who have had most or all of their thyroid gland removed and are taking long-term thyroid hormone medication may be eligible for this study after screening.
Study Details
Timeline
Interventions
Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases